These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 19210158)

  • 21. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative.
    Kasiske B; Cosio FG; Beto J; Bolton K; Chavers BM; Grimm R; Levin A; Masri B; Parekh R; Wanner C; Wheeler DC; Wilson PW;
    Am J Transplant; 2004; 4 Suppl 7():13-53. PubMed ID: 15027968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of statins in preventing adverse cardiovascular outcomes in patients with chronic kidney disease.
    Navaneethan SD; Hegbrant J; Strippoli GF
    Curr Opin Nephrol Hypertens; 2011 Mar; 20(2):146-52. PubMed ID: 21245764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statins and lipid-lowering strategies in cardiorenal patients.
    Bianchi S; Grimaldi D; Bigazzi R
    Contrib Nephrol; 2011; 171():143-150. PubMed ID: 21625103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Chronic kidney disease and statins].
    Matovinović MS
    Lijec Vjesn; 2006; 128(11-12):345-50. PubMed ID: 17212196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Statins and kidney disease].
    Bigazzi R; Grimaldi D; Bianchi S
    G Ital Nefrol; 2012; 29(2):160-73. PubMed ID: 22538946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?
    Athyros VG; Katsiki N; Karagiannis A; Mikhailidis DP
    Expert Opin Pharmacother; 2015; 16(10):1449-61. PubMed ID: 26037614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dyslipidemia in Patients with Kidney Disease.
    Thobani A; Jacobson TA
    Cardiol Clin; 2021 Aug; 39(3):353-363. PubMed ID: 34247749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimizing outcomes in patients with cardiovascular disease and chronic kidney disease.
    Marrs JC
    Am J Manag Care; 2011 Dec; 17 Suppl 15():S403-11. PubMed ID: 22214475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations.
    Vaziri ND; Norris KC
    Blood Purif; 2013; 35(1-3):31-6. PubMed ID: 23343544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LDL-cholesterol lowering and renal outcomes.
    Waters DD
    Curr Opin Lipidol; 2015 Jun; 26(3):195-9. PubMed ID: 25887677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Statins and kidney disease: is the study of heart and renal protection at the cutting edge of evidence?
    Jenkins M; Goldsmith D
    Curr Opin Cardiol; 2012 Jul; 27(4):429-40. PubMed ID: 22678410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [USE OF STATINS IN PATIENTS WITH CHRONIC KIDNEY DISEASE TO PREVENT CARDIOVASCULAR DISEASE].
    Zavidić T; Lodeta B; Lovrinić Đ
    Acta Med Croatica; 2016 Dec; 70(4-5):301-7. PubMed ID: 29087163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of statins in patients with end-stage renal disease.
    Nemerovski CW; Lekura J; Cefaretti M; Mehta PT; Moore CL
    Ann Pharmacother; 2013 Oct; 47(10):1321-9. PubMed ID: 24259696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The lipid story in chronic kidney disease: a long story with a happy end?
    Kujawa-Szewieczek A; Więcek A; Piecha G
    Int Urol Nephrol; 2013 Oct; 45(5):1273-87. PubMed ID: 23054316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipid management in chronic kidney disease, hemodialysis, and transplantation.
    Montague T; Murphy B
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):223-34. PubMed ID: 19217521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Controversies Regarding Lipid Management and Statin Use for Cardiovascular Risk Reduction in Patients With CKD.
    Markossian T; Burge N; Ling B; Schneider J; Pacold I; Bansal V; Leehey D; Stroupe K; Chang A; Kramer H
    Am J Kidney Dis; 2016 Jun; 67(6):965-77. PubMed ID: 26943983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Statins and renal disease: friend or foe?
    Deshmukh A; Mehta JL
    Curr Atheroscler Rep; 2011 Feb; 13(1):57-63. PubMed ID: 21053107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statins in the prevention of cardiovascular events in patients with renal failure.
    Buemi M; Floccari F; Nostro L; Campo S; Caccamo C; Sturiale A; Aloisi C; Giacobbe MS; Frisina N
    Cardiovasc Hematol Disord Drug Targets; 2007 Mar; 7(1):7-13. PubMed ID: 17346123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Statins in chronic kidney disease: what do meta-analyses tell us?
    Upadhyay A
    Clin Exp Nephrol; 2014 Apr; 18(2):278-81. PubMed ID: 24158229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.